Advertisement

European Journal of Clinical Pharmacology

, Volume 74, Issue 11, pp 1513–1521 | Cite as

Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis

  • Fernanda S. Tonin
  • Laiza M. Steimbach
  • Leticia P. Leonart
  • Vinicius L. Ferreira
  • Helena H. Borba
  • Thais Piazza
  • Ariane G. Araújo
  • Fernando Fernandez-Llimos
  • Roberto Pontarolo
  • Astrid Wiens
Pharmacoepidemiology and Prescription

Abstract

Purpose

Although randomized controlled trials (RCTs) are the gold standard for the assessment of clinical outcomes, long-term extension trials (LTEs) and observational cohorts may help generate evidence. Our goal was to compare the discontinuation rates of abatacept, rituximab, and tocilizumab in rheumatoid arthritis (RA) reported in different study designs.

Methods

A systematic review was conducted with searches in PubMed, Scopus, and the Cochrane Library, plus a manual search, for RCTs, LTEs, and observational cohorts reporting discontinuation rates by any of three causes (all-cause, inefficacy, adverse events). Meta-analyses with sensitivity analyses and meta-regressions were conducted.

Results

Of the 111 studies included, 74 were RCTs (n = 55) or LTEs (n = 17) reporting data on abatacept (n = 33), rituximab (n = 10), and tocilizumab (n = 31) and 37 were observational cohort studies (abatacept = 11, rituximab = 8, tocilizumab = 18). The follow-up duration did not differ among the study designs. Discontinuation rates were similar among the drugs but varied among the study designs. Discontinuation rates were significantly higher in cohort studies than those in interventional studies for the three drugs. Sensitivity analyses could not identify patient characteristics associated with these differences. Meta-regression analyses demonstrated no correlation between study follow-up duration and discontinuation rates.

Conclusions

The discontinuation rates reported for non-anti-TNF drugs varied relative to the study design in which they were investigated. Regulatory agencies, price-setting entities, and evidence-gathering researchers should consider the effect of the real-life environment in their decisions and conclusions.

Keywords

Rheumatoid arthritis Statistics and study design Evidence-based medicine Medication Adherence 

Notes

Author contributions

AW, RP, FFL, and FST designed the study and wrote the protocol. LMS, LPL, VLF, HHB, TP, and AGSA screened and abstracted publications. LMS, LPL, VLF, and HHB evaluated methodological quality. FST, AW, and FFL statistically analyzed data. FST and FFL wrote the manuscript, with editorial contributions from LMS, LPL, VLF, HHB, TP, AGSA, AW, and RP. All authors reviewed the manuscript for accuracy and scientific content.

Funding

This work was supported by Fellow of the Brazilian National Council of Scientific and Technological Research—CNPq (grant Universal 14/2014-442095/2014-7).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

228_2018_2524_MOESM1_ESM.docx (17 kb)
ESM 1 (DOCX 17 kb)
228_2018_2524_MOESM2_ESM.doc (221 kb)
ESM 2 (DOC 221 kb)
228_2018_2524_MOESM3_ESM.docx (223 kb)
ESM 3 (DOCX 222 kb)
228_2018_2524_MOESM4_ESM.docx (64 kb)
ESM 4 (DOCX 63 kb)
228_2018_2524_MOESM5_ESM.docx (70 kb)
ESM 5 (DOCX 70 kb)
228_2018_2524_MOESM6_ESM.doc (63 kb)
ESM 6 (DOC 63 kb)

References

  1. 1.
    Anglemyer A, Horvath HT, Bero L (2014) Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev 4:MR000034.  https://doi.org/10.1002/14651858.MR000034.pub2 CrossRefGoogle Scholar
  2. 2.
    Faraoni D, Schaefer ST (2016) Randomized controlled trials vs. observational studies: why not just live together? BMC Anesthesiol 16(1):102.  https://doi.org/10.1186/s12871-016-0265-3 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. Am J Ophthalmol 130(5):688CrossRefGoogle Scholar
  4. 4.
    Buch MH, Aletaha D, Emery P, Smolen JS (2011) Reporting of long-term extension studies: lack of consistency calls for consensus. Ann Rheum Dis 70(6):886–890.  https://doi.org/10.1136/ard.2010.143420 CrossRefPubMedGoogle Scholar
  5. 5.
    Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. N Engl J Med 342(25):1878–1886.  https://doi.org/10.1056/NEJM200006223422506 CrossRefPubMedGoogle Scholar
  6. 6.
    Concato J, Shah N, Horwitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 342(25):1887–1892.  https://doi.org/10.1056/NEJM200006223422507 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Odgaard-Jensen J, Vist GE, Timmer A, Kunz R, Akl EA, Schunemann H, Briel M, Nordmann AJ, Pregno S, Oxman AD (2011) Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 4:MR000012.  https://doi.org/10.1002/14651858.MR000012.pub3 CrossRefGoogle Scholar
  8. 8.
    Ankarfeldt MZ, Adalsteinsson E, Groenwold RH, Ali MS, Klungel OH (2017) A systematic literature review on the efficacy-effectiveness gap: comparison of randomized controlled trials and observational studies of glucose-lowering drugs. Clin Epidemiol 9:41–51.  https://doi.org/10.2147/CLEP.S121991 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P (2007) New therapies for treatment of rheumatoid arthritis. Lancet 370(9602):1861–1874.  https://doi.org/10.1016/S0140-6736(07)60784-3 CrossRefPubMedGoogle Scholar
  10. 10.
    Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509.  https://doi.org/10.1136/annrheumdis-2013-204573 CrossRefPubMedGoogle Scholar
  11. 11.
    Navarro-Millan I, Curtis JR (2013) Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis. Curr Opin Rheumatol 25(3):384–390.  https://doi.org/10.1097/BOR.0b013e32835fc62e CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Johnston SS, McMorrow D, Farr AM, Juneau P, Ogale S (2015) Comparison of biologic disease-modifying antirheumatic drug therapy persistence between biologics among rheumatoid arthritis patients switching from another biologic. Rheumatol Ther 2(1):59–71.  https://doi.org/10.1007/s40744-014-0006-3 CrossRefPubMedGoogle Scholar
  13. 13.
    Remy A, Avouac J, Gossec L, Combe B (2011) Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 29(1):96–103PubMedGoogle Scholar
  14. 14.
    Souto A, Maneiro JR, Gomez-Reino JJ (2016) Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. Rheumatology 55(3):523–534.  https://doi.org/10.1093/rheumatology/kev374 CrossRefPubMedGoogle Scholar
  15. 15.
    Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038.  https://doi.org/10.1016/S0140-6736(16)30173-8 CrossRefPubMedGoogle Scholar
  16. 16.
    Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH (2014) Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 73(3):516–528.  https://doi.org/10.1136/annrheumdis-2013-204577 CrossRefPubMedGoogle Scholar
  17. 17.
    Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358(9285):903–911.  https://doi.org/10.1016/S0140-6736(01)06075-5 CrossRefPubMedGoogle Scholar
  18. 18.
    Negrei C, Bojinca V, Balanescu A, Bojinca M, Baconi D, Spandidos DA, Tsatsakis AM, Stan M (2016) Management of rheumatoid arthritis: impact and risks of various therapeutic approaches. Exp Ther Med 11(4):1177–1183.  https://doi.org/10.3892/etm.2016.3045 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Tanaka Y, Hirata S (2013) Is it possible to withdraw biologics from therapy in rheumatoid arthritis? Clin Ther 35(12):2028–2035.  https://doi.org/10.1016/j.clinthera.2013.10.008 CrossRefPubMedGoogle Scholar
  20. 20.
    Buch MH, Silva-Fernandez L, Carmona L, Aletaha D, Christensen R, Combe B, Emery P, Ferraccioli G, Guillemin F, Kvien TK, Landewe R, Pavelka K, Saag K, Smolen JS, Symmons D, van der Heijde D, Welling J, Wells G, Westhovens R, Zink A, Boers M, European League Against R (2015) Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Ann Rheum Dis 74(6):963–969.  https://doi.org/10.1136/annrheumdis-2013-204948 CrossRefPubMedGoogle Scholar
  21. 21.
    Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. CochraneGoogle Scholar
  22. 22.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed) 339:339.  https://doi.org/10.1136/bmj.b2700 CrossRefGoogle Scholar
  23. 23.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12CrossRefGoogle Scholar
  24. 24.
    Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P (2013) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. In: ed.Google Scholar
  25. 25.
    Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11(2):193–206.  https://doi.org/10.1037/1082-989X.11.2.193 CrossRefPubMedGoogle Scholar
  26. 26.
    Ramiro S, Landewe R, van der Heijde D, Harrison D, Collier D, Michaud K (2015) Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors? RMD Open 1(1):e000155.  https://doi.org/10.1136/rmdopen-2015-000155 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Tarp S, Furst DE, Dossing A, Ostergaard M, Lorenzen T, Hansen MS, Singh JA, Choy EH, Boers M, Suarez-Almazor ME, Kristensen LE, Bliddal H, Christensen R (2016) Defining the optimal biological monotherapy in rheumatoid arthritis: a systematic review and meta-analysis of randomised trials. Semin Arthritis Rheum DOI 46:699–708.  https://doi.org/10.1016/j.semarthrit.2016.09.003 CrossRefGoogle Scholar
  28. 28.
    Gottenberg JE, Brocq O, Perdriger A, Lassoued S, Berthelot JM, Wendling D, Euller-Ziegler L, Soubrier M, Richez C, Fautrel B, Constantin AL, Mariette X, Morel J, Gilson M, Cormier G, Salmon JH, Rist S, Liote F, Marotte H, Bonnet C, Marcelli C, Sellam J, Meyer O, Solau-Gervais E, Guis S, Ziza JM, Zarnitsky C, Chary-Valckenaere I, Vittecoq O, Saraux A, Pers YM, Gayraud M, Bolla G, Claudepierre P, Ardizzone M, Dernis E, Breban MA, Fain O, Balblanc JC, Aberkane O, Vazel M, Back C, Candon S, Chatenoud L, Perrodeau E, Sibilia J, Ravaud P (2016) Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA 316(11):1172–1180.  https://doi.org/10.1001/jama.2016.13512 CrossRefPubMedGoogle Scholar
  29. 29.
    Lee YH, Bae SC (2016) Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis 19(11):1103–1111.  https://doi.org/10.1111/1756-185X.12822 CrossRefPubMedGoogle Scholar
  30. 30.
    Barton S (2000) Which clinical studies provide the best evidence? The best RCT still trumps the best observational study. BMJ 321(7256):255–256CrossRefGoogle Scholar
  31. 31.
    Castillo RC, Scharfstein DO, MacKenzie EJ (2012) Observational studies in the era of randomized trials: finding the balance. J Bone Joint Surg Am 94(Suppl 1):112–117.  https://doi.org/10.2106/JBJS.L.00242 CrossRefPubMedGoogle Scholar
  32. 32.
    Fleischmann R, Kavanaugh A, Smolen J (2013) Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trial. Rheumatology 52(3):409–410.  https://doi.org/10.1093/rheumatology/kes274 CrossRefPubMedGoogle Scholar
  33. 33.
    Naudet F, Maria AS, Falissard B (2011) Antidepressant response in major depressive disorder: a meta-regression comparison of randomized controlled trials and observational studies. PLoS One 6(6):e20811.  https://doi.org/10.1371/journal.pone.0020811 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Edwards JP, Kelly EJ, Lin Y, Lenders T, Ghali WA, Graham AJ (2012) Meta-analytic comparison of randomized and nonrandomized studies of breast cancer surgery. Can J Surg 55(3):155–162.  https://doi.org/10.1503/cjs.023410 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Kardos P, Worsley S, Singh D, Roman-Rodriguez M, Newby DE, Mullerova H (2016) Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD. Int J Chron Obstruct Pulmon Dis 11:2885–2895.  https://doi.org/10.2147/COPD.S118867 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Colditz GA (2010) Overview of the epidemiology methods and applications: strengths and limitations of observational study designs. Crit Rev Food Sci Nutr 50(Suppl 1):10–12.  https://doi.org/10.1080/10408398.2010.526838 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Verde PE, Ohmann C (2015) Combining randomized and non-randomized evidence in clinical research: a review of methods and applications. Res Synth Methods 6(1):45–62.  https://doi.org/10.1002/jrsm.1122 CrossRefPubMedGoogle Scholar
  38. 38.
    Llewellyn-Bennett R, Bowman L, Bulbulia R (2016) Post-trial follow-up methodology in large randomized controlled trials: a systematic review protocol. Syst Rev 5(1):214.  https://doi.org/10.1186/s13643-016-0393-3 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Taylor WJ, Weatherall M (2006) What are open-label extension studies for? J Rheumatol 33(4):642–643PubMedGoogle Scholar
  40. 40.
    Taylor GJ, Wainwright P (2005) Open label extension studies: research or marketing? BMJ 331(7516):572–574.  https://doi.org/10.1136/bmj.331.7516.572 CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Day RO, Williams KM (2007) Open-label extension studies: do they provide meaningful information on the safety of new drugs? Drug Saf 30(2):93–105CrossRefGoogle Scholar
  42. 42.
    Golder S, Loke YK, Bland M (2011) Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med 8(5):e1001026.  https://doi.org/10.1371/journal.pmed.1001026 CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Hannan EL (2008) Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv 1(3):211–217.  https://doi.org/10.1016/j.jcin.2008.01.008 CrossRefPubMedGoogle Scholar
  44. 44.
    Malmivaara A (2016) Clinical impact research—how to choose experimental or observational intervention study? Ann Med 48(7):492–495.  https://doi.org/10.1080/07853890.2016.1186828 CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Struck R, Baumgarten G, Wittmann M (2014) Cost-efficiency of knowledge creation: randomized controlled trials vs. observational studies. Curr Opin Anaesthesiol 27(2):190–194.  https://doi.org/10.1097/ACO.0000000000000060 CrossRefPubMedGoogle Scholar
  46. 46.
    Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, Hara R, Katayama M, Yoshida S, Nagai K, Son Y, Amuro H, Akashi K, Fujimura T, Hirao M, Yamamoto K, Shintani A, Kumanogoh A, Yoshikawa H (2018) Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis—the ANSWER cohort study. PLoS One 13(3):e0194130.  https://doi.org/10.1371/journal.pone.0194130 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Park SK, Lee MY, Jang EJ, Kim HL, Ha DM, Lee EK (2017) A comparison of discontinuation rates of tofacitinib and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis. Clin Exp Rheumatol 35(4):689–699PubMedGoogle Scholar
  48. 48.
    Frank C, Himmelstein DU, Woolhandler S, Bor DH, Wolfe SM, Heymann O, Zallman L, Lasser KE (2014) Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals. Health Aff 33(8):1453–1459.  https://doi.org/10.1377/hlthaff.2014.0122 CrossRefGoogle Scholar
  49. 49.
    BMJ Publishing Group (2017) Fast-track FDA drug approvals and safety warnings. Drug Ther Bull 55(11):122–123.  https://doi.org/10.1136/dtb.2017.10.0544 CrossRefGoogle Scholar
  50. 50.
    Zupnick A (2017) The impact of faster drug approvals on oncology clinical trial design. In: Strategy O (Ed.) Applied clinical trials edGoogle Scholar
  51. 51.
    Fleming PS, Koletsi D, Dwan K, Pandis N (2015) Outcome discrepancies and selective reporting: impacting the leading journals? PLoS One 10(5):e0127495.  https://doi.org/10.1371/journal.pone.0127495 CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L (2012) Industry sponsorship and research outcome. Cochrane Database Syst Rev 12:MR000033.  https://doi.org/10.1002/14651858.MR000033.pub2 CrossRefPubMedGoogle Scholar
  53. 53.
    Dang A, Kaur K (2016) Comparative effectiveness research and its utility in in-clinic practice. Perspect Clin Res 7(1):9–14.  https://doi.org/10.4103/2229-3485.173780 CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Woolacott N, Corbett M, Jones-Diette J, Hodgson R (2017) Methodological challenges identified for the evaluation of clinical effectiveness in the context of accelerated regulatory approval: an overview. J Clin Epidemiol DOI 90:108–118.  https://doi.org/10.1016/j.jclinepi.2017.07.002 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Fernanda S. Tonin
    • 1
  • Laiza M. Steimbach
    • 1
  • Leticia P. Leonart
    • 1
  • Vinicius L. Ferreira
    • 1
  • Helena H. Borba
    • 2
  • Thais Piazza
    • 1
  • Ariane G. Araújo
    • 1
  • Fernando Fernandez-Llimos
    • 3
  • Roberto Pontarolo
    • 2
  • Astrid Wiens
    • 2
  1. 1.Universidade Federal do ParanáCuritibaBrazil
  2. 2.Department of PharmacyUniversidade Federal do ParanáCuritibaBrazil
  3. 3.Research Institute for Medicines (iMed.ULisboa), Department of Social Pharmacy, Faculty of PharmacyUniversidade de LisboaLisbonPortugal

Personalised recommendations